The authors developed an interferon (IFN)-γ release assay to detect T-cell responses specific to SARS-CoV-2 after overnight stimulation of whole blood with peptide libraries covering the immunodominant sequence domains of the Spike glycoprotein and the Nucleocapsid phosphoprotein.

This study investigated the vaccine hesitancy and coping styles in patients with NMOSD to analyze the relationship between vaccine hesitancy and coping styles, and elucidate the factors influencing vaccine hesitancy.

In this article the authors systematically reviewed and meta-analyzed variations in stroke admissions, rate and timing of reperfusion treatments during the 1st-wave COVID pandemic versus the pre-pandemic timeframe depending on stroke network model adopted.

The aim of this study was to determine the influence of high-efficacy disease modifying therapy on the development of IgG SARS-CoV-2 antibody response in COVID-19 convalescent people with multiple sclerosis.

In this article the authors aimed to study headache character in relation to COVID-19. This was a cross-sectional study.

Using a cross-sectional questionnaire study, the authors examined the experience of patients with PNES at a single Comprehensive Epilepsy Center in New York City.

In this article the authors aimed to evaluate the efficacy of awake prone positioning to prevent intubation or death in patients with severe COVID-19 in a large-scale randomised trial.

In this article the authors conducted a prospective cohort study involving patients with suspected VITT who presented to hospitals in the United Kingdom between March 22 and June 6, 2021.

In this article the authors present 5 cases of COVID-19-associated myelitis with tract-specific involvement of the dorsal and lateral columns and discuss potential pathophysiologic pathways for this unique pattern.

In this study the authors identified breakthrough infections by performing extensive evaluations of health care workers who were symptomatic (including mild symptoms) or had known infection exposure.

This study randomly assigned participants who were enrolled within 96 hours after a household contact received a diagnosis of SARS-CoV-2 infection to receive a total dose of 1200mg of REGEN-COV or matching placebo administered by means of subcutaneous injection.

In this article the authors hypothesized that therapeutic-dose anticoagulation may improve outcomes in noncritically ill patients who are hospitalized with COVID-19.

In this open-label, adaptive, multiplatform, randomized clinical trial, critically ill COVID-19 patients were randomly assigned to a regimen of either therapeutic-dose anticoagulation with heparin or pharmacologic thromboprophylaxis in accordance with local usual care.

In this trial, the authors assigned COVID-19 patients to receive either one unit of convalescent plasma with a high titer of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or a placebo.

Observational study: prospective longitudinal cohort (Green) Authors: Carl H Göbel, Axel Heinze, Sarah Karstedt, Mascha Morscheck, Lilian Tashiro, Anna Cirkel, Qutayba Hamid, Rabih Halwani, Mohamad-Hani Temsah, Malte Ziemann, Siegfried Görg, Thomas Münte, Hartmut Göbel The novel coronavirus SARS-CoV-2 causes the… Continue Reading